Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

NCT03838744 is registered in ClinicalTrials.gov with Italian Sarcoma Group as lead sponsor.

NCT NCT03838744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03838744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Lead sponsor
Italian Sarcoma Group
Phase
Phase 2
Overall status
Completed
Start date
May 20, 2020
Completion date
November 29, 2024
Enrollment
130 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced soft tissue sarcoma